Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders

Checkpoint Inhibitor–Induced Colitis

(2020) Emanuelle Bellaguarda et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy

(2020) J. Haanen et al.   ANNALS OF ONCOLOGY

ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743

(2020) P. Baas et al.   Journal of Thoracic Oncology

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

(2019) Celeste Lebbé et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.

(2019) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors

(2019) Laura C. Kennedy et al.   Journal of the National Comprehensive Cancer Network

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

(2019) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study

(2019) Alice Tison et al.   Arthritis & Rheumatology

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

(2019) Robert J Motzer et al.   LANCET ONCOLOGY

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

(2019) Hamzah Abu-Sbeih et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease

(2018) Noha Abdel-Wahab et al.   ANNALS OF INTERNAL MEDICINE

Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

(2018) Giulia C. Leonardi et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

(2018) Georgina V Long et al.   LANCET ONCOLOGY

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen

(2018) Laura C. Cappelli et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

(2016) A. M. Menzies et al.   ANNALS OF ONCOLOGY

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

(2016) Douglas B. Johnson et al.   JAMA Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER